Pharmacoeconomics: Friend or foe?

Annals of the Rheumatic Diseases

Volumn 65, Issue SUPPL. 3, 2006, Pages

  Drummond, M ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GENERIC DRUG; NEW DRUG;

CLINICAL TRIAL; CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; ECONOMIC EVALUATION; HEALTH CARE; HEALTH CARE COST; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL RESPONSE MODIFIERS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; HUMANS;

EID: 33750373701     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.058602     Document Type: Conference Paper

References (18)

1. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn., Oxford: Oxford University Press, 2005.
2. Commonwealth of Australia. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee: including Economic Analyses. Canberra: Department of Health and Community Services, 1995.
3. Cairns J. Providing guidance to the NHS: the Scottish Medicines Consortium and the National Institute for Clinical Excellence compared. Health Policy 2006;76:134-43.
4. Academy of Managed Care Pharmacy. The AMCP Format for Formulary Submissions. Version 2.1. Alexandria VA: AMCP, April, 2005.
5. Drummond MF. Economic evaluation in health care: is it really useful or are we just kidding ourselves? Aust Econ Rev 2004;37:183-97.
6. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines-similarities, differences and some implications. Value Health 2001;4:225-50.
7. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London: NICE, 2004.
8. Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D, Drummond M, et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol 2003;30:891-6.
9. Anis AH, Gagnon Y. Using economic evaluations to make formulary coverage decisions: so much for guidelines. Pharmacoeconomics 2000;18:55-62.
10. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004;329:224-7.
11. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437-52.
12. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision-making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 2001;19:1103-9.
13. Kobelt G, Jönsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003;42:326-35.
14. Bansback N, Brennan A, Ghatnekar O. The cost-effectiveness of adalimumab in the treatment of moderate to severe rheumatoid arthritis patients in Sweden. Ann Rheum Dis 2005;64:995-1002.
15. Drummond MF, Barbieri M, Wong JB. Analytic choices in economic models of treatments for rheumatoid arthritis: what makes a difference? Med Decis Making 2005;25:520-33.
16. Kobelt G, Andlin-Sobocki P, Brophy S, Jonsson L, Calin A, Braun J. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology 2004;43:1158-66.
17. National Institute for Health and Clinical Excellence. Osteoarthritis and Rheumatoid Arthritis-coxll Inhibitors, Technology Appraisal No.27. London: NICE, July, 2001.
18. Garrison L, Towse A. The drug budget silo mentality in Europe: an overview. Value Health 2003;6(suppl 1):S1-9.